Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 BiondVax PharmaceuticalsBioCardiaPharmaCyte BiotechaTyr PharmaAcorda Therapeutics
SymbolNASDAQ:BVXVNASDAQ:BCDAOTCMKTS:PMCBNASDAQ:LIFENASDAQ:ACOR
Price Information
Current Price$3.09$3.98$0.02$3.77$4.19
52 Week RangeN/ABuyN/ABuyHold
MarketRank™
Overall Score0.51.50.51.51.4
Analysis Score0.03.30.03.53.0
Community Score2.52.52.42.32.2
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.80.0
Earnings & Valuation Score0.00.60.00.61.9
Analyst Ratings
Consensus RecommendationN/ABuyN/ABuyHold
Consensus Price TargetN/A$9.25N/A$15.67$23.67
% Upside from Price TargetN/A132.41% upsideN/A315.56% upside464.84% upside
Trade Information
Market Cap$35.08 million$65.03 million$39.12 million$60.36 million$39.76 million
Beta2.411.980.492.170.75
Average Volume928,060291,52616,218,1691,394,363909,914
Sales & Book Value
Annual RevenueN/A$710,000.00N/A$420,000.00$192.41 million
Price / SalesN/A91.59N/A143.720.21
CashflowN/AN/AN/AN/A$18.22 per share
Price / CashN/AN/AN/AN/A0.23
Book Value($2.88) per share$0.35 per shareN/A$5.40 per share$38.82 per share
Price / BookN/A11.37N/A0.700.11
Profitability
Net Income$-31,600,000.00$-14,710,000.00$-3,830,000.00$-23,600,000.00$-272,970,000.00
EPS($3.60)($2.61)N/A($7.03)($11.94)
Trailing P/E RatioN/AN/A0.00N/A0.76
Forward P/E Ratio∞N/A∞N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-5,103.95%N/A-202.02%29.71%
Return on Equity (ROE)N/A-496.87%-57.82%-52.75%-8.60%
Return on Assets (ROA)-135.18%-178.90%-49.63%-38.40%-3.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.05%N/AN/A0.52%
Current Ratio6.48%1.99%5.92%4.76%1.09%
Quick Ratio6.48%1.99%5.92%4.76%0.88%
Ownership Information
Institutional Ownership Percentage4.04%9.01%0.02%55.82%N/A
Insider Ownership Percentage6.03%40.90%N/A9.44%6.80%
Miscellaneous
Employees2524439167
Shares Outstanding11.35 million16.34 million2.39 billion16.01 million9.49 million
Next Earnings Date6/29/2021 (Estimated)5/21/2021 (Estimated)8/12/2021 (Estimated)5/11/2021 (Estimated)5/4/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
Chef with Parkinson’s, Zarela Martinez, and Acorda Open Mexican Food SeriesChef with Parkinson’s, Zarela Martinez, and Acorda Open Mexican Food Series
parkinsonsnewstoday.com - April 16 at 9:56 AM
Bullish or Bearish for Acorda Therapeutics, Inc. (NASDAQ:ACOR) in 2021Bullish or Bearish for Acorda Therapeutics, Inc. (NASDAQ:ACOR) in 2021
stocksregister.com - April 12 at 8:00 PM
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Up 40.6% in MarchAcorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Up 40.6% in March
americanbankingnews.com - April 1 at 1:14 AM
Using the Action in Acorda Therapeutics $ACOR to our AdvantageUsing the Action in Acorda Therapeutics $ACOR to our Advantage
marketwatch.com - March 16 at 9:44 AM
Vertex (VRTX) Type I Diabetes Candidate Clinical Study BeginsVertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
finance.yahoo.com - March 11 at 12:17 PM
Life sciences intellectual property licensing at the Massachusetts Institute of TechnologyLife sciences intellectual property licensing at the Massachusetts Institute of Technology
nature.com - March 10 at 9:08 PM
Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - March 10 at 1:34 PM
Single-payer health bill makes its way back to LegislatureSingle-payer health bill makes its way back to Legislature
crainsnewyork.com - March 10 at 8:33 AM
The Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Just Boosted Their Forecasts By A Dazzling AmountThe Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Just Boosted Their Forecasts By A Dazzling Amount
finance.yahoo.com - March 9 at 8:19 AM
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual ConferenceAcorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
finance.yahoo.com - March 8 at 7:44 PM
QIAGEN (QGEN) Unveils Digital Platform for Syndromic TestingQIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
finance.yahoo.com - March 5 at 6:04 PM
Acorda Therapeutics, Inc. 2020 Q4 - Results - Earnings Call PresentationAcorda Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 5 at 2:16 PM
11 Stocks Moving In Thursdays After-Hours Session11 Stocks Moving In Thursday's After-Hours Session
msn.com - March 4 at 8:51 PM
Acorda: Q4 Earnings SnapshotAcorda: Q4 Earnings Snapshot
finance.yahoo.com - March 4 at 8:51 PM
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsAcorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:51 PM
Acorda Therapeutics is about to announce earnings — heres what Wall Street expectsAcorda Therapeutics is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - March 2 at 1:31 PM
Novavax (NVAX) Loss Widens in Q4, Revenues Top EstimatesNovavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
finance.yahoo.com - March 2 at 1:31 PM
Horizons (HZNP) Shares Rise on Q4 Earnings & Sales BeatHorizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat
msn.com - February 25 at 2:01 PM
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
finance.yahoo.com - February 25 at 9:00 AM
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?
nasdaq.com - February 24 at 7:58 AM
Acorda Therapeutics Announces Departure of Chief, Business OperationsAcorda Therapeutics Announces Departure of Chief, Business Operations
finance.yahoo.com - February 19 at 8:40 AM
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer DrugSeagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
finance.yahoo.com - February 11 at 12:32 PM
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to CatalentAcorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
finance.yahoo.com - February 11 at 7:32 AM
Acorda (ACOR) to Report Q4 Earnings: Whats in the Cards?Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 8 at 2:02 PM
Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05BHorizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B
finance.yahoo.com - February 2 at 8:03 PM
DateCompanyBrokerageAction
4/16/2021BioCardiaDawson JamesDowngrade
9/21/2020BioCardiaAlliance Global PartnersInitiated Coverage
8/14/2020BioCardiaMaxim GroupInitiated Coverage
11/26/2019BioCardiaBrookline Capital ManagementReiterated Rating
3/30/2021aTyr PharmaOppenheimerBoost Price Target
3/22/2021aTyr PharmaRoth CapitalBoost Price Target
8/17/2020aTyr PharmaHC WainwrightUpgrade
8/30/2019aTyr PharmaCitigroupSet Price Target
3/26/2019aTyr PharmaWilliam BlairReiterated Rating
10/8/2018aTyr PharmaPiper Jaffray CompaniesLower Price Target
8/15/2018aTyr PharmaBMO Capital MarketsLower Price Target
1/13/2021Acorda TherapeuticsCowenBoost Price Target
8/11/2020Acorda TherapeuticsJefferies Financial GroupReiterated Rating
2/16/2020Acorda TherapeuticsJPMorgan Chase & Co.Reiterated Rating
8/2/2019Acorda TherapeuticsStifel NicolausLower Price Target
8/2/2019Acorda TherapeuticsWedbushLower Price Target
8/2/2019Acorda TherapeuticsCantor FitzgeraldLower Price Target
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.